2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07E.07 Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations

EP.07E.07 Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations

Back to course

Pdf Summary

This document presents a study evaluating the use of aumolertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), as adjuvant therapy in patients with completely resected, stage IA2-IIIA non-small cell lung cancer (NSCLC) that possess uncommon EGFR mutations. These mutations are historically associated with reduced sensitivity to conventional EGFR-TKIs, making treatment challenging.<br /><br />Conducted as a single-arm, retrospective clinical trial, the study collected data from eight NSCLC patients with uncommon EGFR mutations, specifically G719X/L861Q/S768I, exon 20 insertions, among others. The median age of participants was 68.5 years, with an equal gender distribution. The primary objectives were to assess disease-free survival (DFS), safety, and tolerability, along with exploratory endpoints like recurrence patterns and central nervous system disease-free survival (CNS DFS).<br /><br />The results were promising; at a median follow-up of 18.9 months, only one patient experienced recurrence, and no CNS recurrences were reported. The DFS rates were 100% at one year and 80% at two years for the overall cohort, while the stage I subgroup achieved a 100% two-year DFS rate. In terms of safety, no grade 3 adverse events were reported, and aumolertinib was well tolerated, with only mild adverse reactions such as rash and cough.<br /><br />The study concludes that adjuvant aumolertinib holds substantial promise for this patient population, particularly given its excellent safety profile. Ongoing long-term follow-up is anticipated to provide additional insights into survival outcomes. Acknowledgement was given to all participants, their families, caregivers, and the entire study team for their contributions.

Asset Subtitle

Jiayue Ye

Meta Tag

Speaker Jiayue Ye

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

aumolertinib

EGFR-TKI

non-small cell lung cancer

uncommon EGFR mutations

adjuvant therapy

disease-free survival

safety

tolerability

clinical trial

recurrence patterns